KR102421388B1 - 신규 아미노 피리미딘 유도체 - Google Patents

신규 아미노 피리미딘 유도체 Download PDF

Info

Publication number
KR102421388B1
KR102421388B1 KR1020227009823A KR20227009823A KR102421388B1 KR 102421388 B1 KR102421388 B1 KR 102421388B1 KR 1020227009823 A KR1020227009823 A KR 1020227009823A KR 20227009823 A KR20227009823 A KR 20227009823A KR 102421388 B1 KR102421388 B1 KR 102421388B1
Authority
KR
South Korea
Prior art keywords
formula
compound
int
optionally substituted
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227009823A
Other languages
English (en)
Korean (ko)
Other versions
KR20220044370A (ko
Inventor
다니엘라 앙스트
프랑수아 게시에
안나 불페티
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20220044370A publication Critical patent/KR20220044370A/ko
Application granted granted Critical
Publication of KR102421388B1 publication Critical patent/KR102421388B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227009823A 2013-11-29 2014-11-28 신규 아미노 피리미딘 유도체 Active KR102421388B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
EP13195081.8 2013-11-29
PCT/IB2014/066422 WO2015079417A1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
KR1020167013830A KR102380539B1 (ko) 2013-11-29 2014-11-28 신규 아미노 피리미딘 유도체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167013830A Division KR102380539B1 (ko) 2013-11-29 2014-11-28 신규 아미노 피리미딘 유도체

Publications (2)

Publication Number Publication Date
KR20220044370A KR20220044370A (ko) 2022-04-07
KR102421388B1 true KR102421388B1 (ko) 2022-07-18

Family

ID=49674216

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227009823A Active KR102421388B1 (ko) 2013-11-29 2014-11-28 신규 아미노 피리미딘 유도체
KR1020167013830A Active KR102380539B1 (ko) 2013-11-29 2014-11-28 신규 아미노 피리미딘 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167013830A Active KR102380539B1 (ko) 2013-11-29 2014-11-28 신규 아미노 피리미딘 유도체

Country Status (42)

Country Link
US (6) US9512084B2 (enExample)
EP (5) EP4606377A3 (enExample)
JP (2) JP6342495B2 (enExample)
KR (2) KR102421388B1 (enExample)
CN (2) CN110172056B (enExample)
AP (1) AP2016009158A0 (enExample)
AR (1) AR098549A1 (enExample)
AU (1) AU2014356069B2 (enExample)
BR (1) BR112016010397B1 (enExample)
CA (1) CA2926908C (enExample)
CL (1) CL2016001055A1 (enExample)
CR (1) CR20160244A (enExample)
CU (1) CU24384B1 (enExample)
CY (3) CY1119705T1 (enExample)
DK (3) DK3299368T3 (enExample)
EA (1) EA031218B1 (enExample)
EC (1) ECSP16054826A (enExample)
ES (4) ES2947770T3 (enExample)
FI (1) FI3689865T3 (enExample)
HR (3) HRP20171999T1 (enExample)
HU (3) HUE037588T2 (enExample)
IL (1) IL244943B (enExample)
JO (1) JO3314B1 (enExample)
LT (3) LT3689865T (enExample)
MA (1) MA39055B1 (enExample)
MX (1) MX367911B (enExample)
MY (2) MY179059A (enExample)
NO (1) NO3074386T3 (enExample)
NZ (1) NZ718835A (enExample)
PE (1) PE20160869A1 (enExample)
PH (1) PH12016500791A1 (enExample)
PL (3) PL3299368T3 (enExample)
PT (3) PT3299368T (enExample)
RS (3) RS64275B1 (enExample)
SI (3) SI3299368T1 (enExample)
SV (1) SV2016005206A (enExample)
TN (1) TN2016000128A1 (enExample)
TW (1) TWI652261B (enExample)
UA (1) UA117256C2 (enExample)
UY (1) UY35858A (enExample)
WO (1) WO2015079417A1 (enExample)
ZA (1) ZA201602275B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
KR102487608B1 (ko) 2014-04-07 2023-01-12 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
CN107109419B (zh) 2014-07-21 2020-12-22 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
RU2751660C2 (ru) 2014-07-21 2021-07-15 Новартис Аг Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR102804360B1 (ko) 2014-09-17 2025-05-12 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US20180140602A1 (en) * 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CA2981751A1 (en) 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
MX2019003886A (es) 2016-10-07 2019-08-05 Novartis Ag Receptores de antigenos quimericos para el tratamiento del cancer.
KR20190104528A (ko) 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포들 투여를 결정하는 방법
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
AU2018291032A1 (en) 2017-06-29 2020-01-16 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
EP3703750B1 (en) 2017-11-01 2024-12-04 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
AR113796A1 (es) 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)
WO2019109053A1 (en) 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
MX2021000925A (es) 2018-07-25 2021-03-31 Novartis Ag Inhibidores de inflamasoma nlrp3.
EA202190557A1 (ru) 2018-08-29 2021-07-13 Асерта Фарма Б.В. СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА
PE20211058A1 (es) 2018-11-01 2021-06-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
JP2022513062A (ja) 2018-11-16 2022-02-07 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法
KR20210117260A (ko) 2018-11-30 2021-09-28 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료방법
CN113365660A (zh) 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
CA3137790A1 (en) * 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor
SI3972603T1 (sl) * 2019-05-23 2025-02-28 Novartis Ag Postopki zdravljenja sjogrenovega sindroma z uporabo zaviralca brutonove tirozin kinaze
WO2020234782A1 (en) * 2019-05-23 2020-11-26 Novartis Ag Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
US20230121818A1 (en) * 2019-12-23 2023-04-20 Biogen Ma Inc. Btk inhibitors
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
IL299091A (en) 2020-08-14 2023-02-01 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and their medicinal uses
WO2022033569A1 (zh) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
WO2022162513A1 (en) 2021-01-26 2022-08-04 Novartis Ag Pharmaceutical composition
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
CA3229887A1 (en) 2021-09-03 2023-03-09 Novartis Ag Lou064 for treating multiple sclerosis
EP4448114A1 (en) 2021-12-14 2024-10-23 Novartis AG Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CA3263560A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics Inc GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
WO2025061148A1 (zh) * 2023-09-22 2025-03-27 江苏恒瑞医药股份有限公司 杂芳基类化合物、其制备方法及其在医药上的应用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
WO2025210469A2 (en) 2024-04-02 2025-10-09 Novartis Ag Process of preparing remibrutinib substantially free of nitrosamine impurity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013083666A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
JP2004533209A (ja) 2000-10-23 2004-11-04 ブリストル−マイヤーズ　スクイブ　カンパニー ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用
KR100748386B1 (ko) 2000-11-07 2007-08-10 노파르티스 아게 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
WO2004039956A2 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7365096B2 (en) 2002-12-09 2008-04-29 Board Of Regents, The University Of Texas System Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
MXPA06007640A (es) 2004-01-12 2007-04-17 Cytopia Res Pty Ltd Inhibidores de quinasa selectivos.
CN101223141A (zh) 2005-03-10 2008-07-16 Cgi药品股份有限公司 特定取代的酰胺，其制备方法和使用方法
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
SG166093A1 (en) 2006-09-22 2010-11-29 Pharmacyclics Inc Inhibitors of brutonæs tyrosine kinase
DK2134374T3 (en) 2007-03-14 2014-02-24 Bionsil S R L In Liquidazione BTK-INHIBITORS FOR USE IN PROCESSING chemotherapeutic agent RESISTANT TUMORS Epithelial
US8426424B2 (en) 2008-05-06 2013-04-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
MX2010013478A (es) 2008-07-02 2010-12-20 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de cinasa.
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (en) 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EP2539343B1 (en) * 2010-02-26 2015-12-30 Evotec International GmbH Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
JP6147727B2 (ja) 2011-04-01 2017-06-14 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
AU2012255759C1 (en) 2011-05-17 2025-10-23 Principia Biopharma, Inc. Kinase inhibitors
SG10201604682VA (en) 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
AU2012275275A1 (en) 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
CA2841111A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel pyrrolo pyrimidine derivatives
EP2742138B1 (en) 2011-08-09 2020-06-24 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
EP2824099A4 (en) 2012-03-09 2015-11-11 Carna Biosciences Inc NOVEL TRIAZINE DERIVATIVE
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2014025976A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
JP6401169B2 (ja) 2012-10-04 2018-10-03 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013083666A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
SI3689865T1 (sl) 2023-07-31
NO3074386T3 (enExample) 2018-03-10
IL244943B (en) 2020-04-30
CA2926908C (en) 2021-10-26
EP4219478A1 (en) 2023-08-02
JP2018141005A (ja) 2018-09-13
DK3299368T3 (da) 2020-05-25
HRP20230585T1 (hr) 2023-09-01
US20200010426A1 (en) 2020-01-09
PH12016500791B1 (en) 2016-06-13
LT3689865T (lt) 2023-07-10
SI3074386T1 (en) 2018-02-28
BR112016010397A8 (pt) 2020-04-22
MX2016006908A (es) 2016-08-17
NZ718835A (en) 2021-12-24
EA031218B1 (ru) 2018-12-28
JP6342495B2 (ja) 2018-06-13
CN105683181B (zh) 2019-04-23
SI3299368T1 (sl) 2020-07-31
CL2016001055A1 (es) 2016-10-28
US11673868B2 (en) 2023-06-13
HUE062248T2 (hu) 2023-10-28
CY1122924T1 (el) 2021-10-29
LT3299368T (lt) 2020-05-25
US10457647B2 (en) 2019-10-29
TWI652261B (zh) 2019-03-01
UA117256C2 (uk) 2018-07-10
AR098549A1 (es) 2016-06-01
EP4606377A3 (en) 2025-11-26
FI3689865T3 (fi) 2023-06-12
AU2014356069A1 (en) 2016-05-05
HRP20171999T1 (hr) 2018-02-09
US9512084B2 (en) 2016-12-06
EP3074386B1 (en) 2017-10-11
HRP20200775T1 (hr) 2020-07-24
RS64275B1 (sr) 2023-07-31
US20180251432A1 (en) 2018-09-06
PL3074386T3 (pl) 2018-03-30
US20160235746A1 (en) 2016-08-18
UY35858A (es) 2015-06-30
EP4219478B1 (en) 2025-06-11
IL244943A0 (en) 2016-05-31
US20230312483A1 (en) 2023-10-05
MX367911B (es) 2019-09-11
PT3689865T (pt) 2023-06-16
KR102380539B1 (ko) 2022-03-29
HUE037588T2 (hu) 2018-09-28
DK3074386T3 (en) 2018-01-22
PT3299368T (pt) 2020-05-28
EA201691125A1 (ru) 2016-09-30
PT3074386T (pt) 2017-11-15
PL3689865T3 (pl) 2023-07-31
MA39055A1 (fr) 2018-02-28
AP2016009158A0 (en) 2016-04-30
CR20160244A (es) 2016-07-29
EP3689865B1 (en) 2023-03-29
PE20160869A1 (es) 2016-09-08
PH12016500791A1 (en) 2016-06-13
SV2016005206A (es) 2016-11-21
KR20220044370A (ko) 2022-04-07
LT3074386T (lt) 2017-12-27
HK1223368A1 (en) 2017-07-28
JP6667573B2 (ja) 2020-03-18
CA2926908A1 (en) 2015-06-04
CN105683181A (zh) 2016-06-15
CY1126056T1 (el) 2023-11-15
WO2015079417A1 (en) 2015-06-04
BR112016010397B1 (pt) 2023-04-11
DK3689865T3 (en) 2023-06-19
TN2016000128A1 (en) 2017-10-06
CN110172056B (zh) 2022-04-19
ES2947770T3 (es) 2023-08-18
CU20160078A7 (es) 2016-09-30
ES3040769T3 (en) 2025-11-04
ZA201602275B (en) 2017-08-30
KR20160088877A (ko) 2016-07-26
CN110172056A (zh) 2019-08-27
RS56657B1 (sr) 2018-03-30
TW201609666A (zh) 2016-03-16
EP3299368B1 (en) 2020-02-26
US11180460B2 (en) 2021-11-23
RS60251B1 (sr) 2020-06-30
MY191381A (en) 2022-06-22
MA39055B1 (fr) 2018-10-31
CY1119705T1 (el) 2018-06-27
HUE049794T2 (hu) 2020-10-28
ECSP16054826A (es) 2017-10-31
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
AU2014356069B2 (en) 2017-06-15
PL3299368T3 (pl) 2020-08-10
EP4606377A2 (en) 2025-08-27
US20150152068A1 (en) 2015-06-04
JP2016538313A (ja) 2016-12-08
EP3299368A1 (en) 2018-03-28
CU24384B1 (es) 2019-03-04
MY179059A (en) 2020-10-26
US20220041561A1 (en) 2022-02-10
ES2791525T3 (es) 2020-11-04
ES2655527T3 (es) 2018-02-20
HK1252317A1 (en) 2019-05-24
EP3074386A1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
US11673868B2 (en) Amino pyrimidine derivatives
HK40089302B (en) Method of preparing amino pyrimidine derivatives
HK40024076B (en) Novel amino pyrimidine derivatives
HK40024076A (en) Novel amino pyrimidine derivatives
HK1252317B (en) Novel amino pyrimidine derivatives
HK1223368B (en) Novel amino pyrimidine derivatives

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220324

Application number text: 1020167013830

Filing date: 20160525

PA0201 Request for examination
PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220503

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220712

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220713

End annual number: 3

Start annual number: 1

PG1601 Publication of registration